Suchergebnisse - "Agbarya, Abed"

PubPharm (6)

1

Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells

enthalten in: Translational oncology | 2024

von Carmi, Y. | Agbarya, A. | Khamaisi, H. | +5

2

Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer : A Retrospective, Single Institution Experience

enthalten in: Oncology | 2022

von Shalata, W. | Yakobson, A. | Weissmann, S. | +5

3

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10

4

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-$ ABL1^{T315I} $ and BCR-$ ABL1^{T315I-E255K} $

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10

5

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-$ ABL1^{T315I} $ and BCR-$ ABL1^{T315I-E255K} $

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10

6

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-$ ABL1^{T315I} $ and BCR-$ ABL1^{T315I-E255K} $

enthalten in: Annals of hematology | 2021

von Mian, A. | Haberbosch, I. | Khamaisie, H. | +10

1
[1]